Inflection Biosciences Ltd is a pioneering drug development company focused on the discovery and advancement of innovative small molecule therapeutics for cancer, autoimmune, and inflammatory diseases. Their strategy involves identifying and licensing the most promising drug discovery projects globally, leading them through pre-clinical and early clinical stages, and ultimately partnering with external organizations for later stage clinical development and commercialization. Among their impressive pipeline, IBL-101 stands out as a pan-PIM kinase inhibitor currently undergoing preclinical development for the treatment of autoimmune and inflammatory diseases.

Additionally, they are developing IBL-202, a first-in-class dual PIM kinase and PI3K inhibitor targeting aggressive B-cell malignancies, T-cell lymphoma, and acute myeloid leukemia. In collaboration with AUM Biosciences, Inflection Biosciences also boasts a first-in-class compound known as AUM302, a PIM/PI3K/mTOR inhibitor. With a dedicated team of experts, including directors and advisors, Inflection Biosciences is committed to revolutionizing the field of drug development to address critical unmet medical needs.

Learn more about their work and explore partnership opportunities on their website